Menopause hormone therapy and youthful skin: where clinical evidence and expert caution meet

Reader questions answered

Which measurable skin changes accompany menopause?

Studies associate the menopause transition with reduced dermal collagen and skin thickness, lower elasticity and hydration, and changes in skin-barrier function. Dryness and wrinkling can accompany these changes. Researchers can measure some of them using techniques such as ultrasound or skin biopsy, although a measurement is not necessarily the same as a change a person notices in the mirror.

These are population-level associations, not a timetable for every person. Chronological aging, sun exposure, smoking and other factors also influence skin. Looking at someone’s face cannot reveal how much of a particular change is due to falling estrogen. The 2025 dermatology review brings these observations together, but it is a narrative review, not a definitive test of each cause.

Which clinical trials studied hormone therapy and skin outcomes?

The clearest positive structural result in the dossier comes from a randomized, double-blind, placebo-controlled trial of 60 postmenopausal women. According to the dermatology review, 30 were assigned conjugated estrogen and 30 placebo. After 12 months, the estrogen group had significant increases in skin and dermal thickness; the placebo group did not have a statistically significant change.

The review reports increases within the estrogen group of 11.5% in ultrasound-measured skin thickness and 33% in biopsy-measured dermal thickness. Those figures should not be read as the treatment’s percentage advantage over placebo: the primary abstract does not establish a placebo-adjusted percentage effect. Measurements were taken at the hip, not the face. The trial was also too small to characterize uncommon harms, and its funder was not verified.

A different result comes from a larger multicenter randomized trial, described in the dermatology review. It involved 485 postmenopausal women and compared two low-dose systemic norethindrone acetate/ethinyl estradiol combinations with placebo. The review reports no significant improvement in mild-to-moderate facial aging, including the assessed wrinkles, laxity, texture and elasticity.

There is an important documentation problem: the review’s text describes that trial as 48 weeks long, while its table says four years. The original paper needs checking before its duration can be stated confidently. The dossier also describes a KEEPS ancillary trial that found no significant overall facial wrinkle or rigidity benefit over four years, but its original record was not fully checked for corrections or funding. Taken together, these findings make a useful distinction: changing skin structure at one body site does not establish a noticeable, durable facial improvement.

Are cosmetic improvements an accepted reason to start systemic therapy?

No. In the dermatology review, hormone therapy is not indicated solely for estrogen-deficient skin. The ACOG menopause guideline addresses systemic treatment for appropriate patients with bothersome vasomotor symptoms, such as hot flashes, and related sleep disturbance; it is not a cosmetic skin-treatment guideline.

A person who has a separate, established reason to use systemic therapy can discuss skin changes as a possible incidental effect. That is different from assuming an appearance benefit will occur or that it makes the overall benefit–risk balance favorable. The available trials do not settle whether a future skin-specific hormonal treatment might have a different balance.

How do professional guidance bodies weigh benefits and harms?

ACOG supports individualized decisions for appropriate patients with bothersome symptoms, taking age, timing and personal risks into account. NICE guidance likewise calls for discussion of benefits, risks and routes of hormone therapy. The VA/DoD guideline considers both hormone and nonhormone options. These documents address clinical care, not a new cosmetic indication.

Some patients may discuss systemic therapy for bone-loss prevention in appropriate circumstances. Local vaginal treatment can address genitourinary symptoms without prescribing systemic treatment just for skin. Systemic therapy is not recommended solely to prevent cardiovascular disease or dementia.

Labeling changes also need context. According to the US Office on Women’s Health, the FDA requested boxed-warning changes in November 2025 and approved revised labeling for six products in February 2026. Risk information remains elsewhere in labeling, and the endometrial cancer boxed warning remains on systemic estrogen-only products. A label change does not make every product identical or treatment risk-free.

How do age, personal history, route and timing affect decisions?

For eligible patients with bothersome symptoms, the overall balance is generally more favorable when systemic therapy starts before age 60 or within 10 years of menopause. Neither threshold is an automatic guarantee of safety. The ACOG guideline and NICE recommendations emphasize individual assessment rather than a one-size-fits-all rule.

A clinician should review a history of blood clots, stroke, heart attack, hormone-sensitive cancer, unexplained vaginal bleeding or liver disease. Whether a person has a uterus matters: systemic estrogen generally requires accompanying endometrial protection in someone with a uterus. Dose, regimen and duration matter too.

Route is another part of the conversation. Observational evidence suggests estrogen delivered through the skin may carry less clot risk than oral estrogen, but it is not risk-free. Precise differences between routes and progestogens for every outcome are not established by head-to-head randomized trials. Ask about the specific product rather than assuming that a patch, pill or other formulation has the same risk profile.

Where do dermatologists and menopause specialists genuinely disagree?

The evidence here shows a difference in emphasis, not a verified specialty-wide split. The dermatology review argues that estrogen-related skin changes deserve attention and further research, while acknowledging inconsistent trial findings and no skin-only indication for systemic therapy. Menopause guidance, including ACOG’s, focuses on established symptom relief and individualized systemic risks.

Those positions can coexist: a skin outcome can matter to patients without being sufficiently proven or safe enough to justify systemic treatment on its own. The dossier does not establish that dermatologists generally recommend hormones solely for appearance, nor does it verify an attributed head-to-head dispute between experts. The dermatology review was funded by Merz Aesthetics, an aesthetics company; that relationship is worth considering alongside its interpretation of the evidence.

What are safer non-hormonal options for appearance concerns?

Start with sun protection and a moisturizer. A dermatologist can also discuss whether a topical retinoid for photoaging is suitable, including the possibility of irritation. These measures address skin directly rather than exposing the whole body to systemic hormone treatment, though none is entirely risk-free. The dermatology review discusses nonhormonal approaches alongside hormonal ones.

Procedures are another possible discussion, not an automatic next step. Ask about cost, pigmentation changes and scarring, and whether evidence applies specifically to menopausal patients. The dossier does not verify procedure prices, so no reliable cost estimate can be given here.

Supplements deserve the same scrutiny. A systematic review of isoflavones reported small pooled improvements in skin roughness and wrinkle-surface measures, but its 2,657 participants across 47 trials covered multiple outcomes—not all skin outcomes. Isoflavones have estrogen-like activity and should not be assumed suitable for everyone. Facial hormone creams are hormonal products, not equivalent to nonhormonal skincare; absorption and long-term safety depend on formulation and remain uncertain.

What should a reader discuss with a qualified clinician?

Begin with the actual concern: dryness, a change in texture, or another symptom—and whether a treatable skin condition might be involved. Mention other menopause symptoms, age and time since menopause, uterus status, bleeding, relevant cancer, clot, cardiovascular or liver history, and current medicines.

If systemic therapy has a legitimate indication, ask what symptom improvement is realistic, which nonhormonal alternatives are available, how route and endometrial protection affect the choice, and what the specific product’s risks are. Agree on a review plan. ACOG recommends assessing efficacy and tolerability at three months and then at least annually. Report persistent or new postmenopausal bleeding promptly for assessment; NICE updated its advice on seeking help for bleeding during systemic therapy in 2026.

Sources and conflicts

The primary hip trial provides direct randomized evidence, but its funding was not established and its abstract does not supply the review’s percentage figures. The facial-trial account is secondary; its duration is inconsistent within the review. The same review also gives conflicting descriptions of hydration results in another trial, so that outcome needs the original report before drawing a conclusion. The review disclosed Merz Aesthetics funding.

The guidance cited is from US and UK bodies; indications and rules elsewhere were not established. The dossier’s search was bounded rather than exhaustive, and the original KEEPS and larger facial-trial records were not fully checked for corrections or retractions. Evidence was web-cited but not independently fact-checked.